BetterLife Closes $100M Offering for Neurological Drug Pipeline

VANCOUVER – BetterLife Pharma Inc. closed a US$100 million public offering, providing capital to take its lead candidate through Phase I and Phase II clinical trials for cluster headache and migraine. Deep Track Capital led the financing, joined by Coastlands Capital, Marshall Wace, RA Capital Management, and Perceptive Advisors – a group of specialized healthcare institutional investors.

The offering comprised 447 million common shares and over 107 million pre-funded warrants at CA$0.25 per share, yielding CA$138.75 million in gross proceeds. Bloom Burton Securities served as lead agent alongside Haywood Securities.

The company’s lead asset, BETR-001, is the active stereoisomer of 2-bromo-LSD – a fully non-hallucinogenic derivative of LSD that acts as a 5-HT2A partial agonist and potent neuroplastogen. The compound was initially developed by Albert Hofmann in the 1950s, as part of the original research from which LSD was also derived. It carries no scheduling designation under U.S. federal drug law and is designed for oral, at-home administration, separating it from virtually every other LSD-adjacent therapy in clinical development.

The therapeutic rationale is grounded in published human evidence. In a clinical pilot study, 2-bromo-LSD (the racemic form) reduced both the frequency and intensity of attacks in cluster headache patients, with no hallucinations or distortions and no cardiopulmonary adverse events, providing rare, mechanism-confirming clinical evidence for BETR-001’s activity in a severe headache disorder.

Cluster headache is broadly regarded as one of the most debilitating pain conditions in neurology. Chronic cluster headache causes severe, recurrent attacks that respond poorly to existing therapies, and many chronic migraine patients exhaust available preventives without durable relief. Chronic migraine is also the leading cause of disability in adults under fifty globally, with tens of millions of patients cycling through standard-of-care options that provide only partial or temporary benefit.

BetterLife’s synthesis patent for BETR-001 eliminates controlled substance manufacturing hurdles, and its pending patent for composition and method of use covers treatment of various neurological disorders through approximately 2042. The company has contracted Syner-G BioPharma for GMP manufacturing and Nucro-Technics for the final IND-enabling GLP toxicology study, with an IND filing and Phase 1 start projected for Q1 2027.

Net proceeds will fund Phase 1A studies in healthy volunteers, concurrent Phase 1B trials for cluster headache and migraine, Phase 2 trials for both conditions, and a post-Phase 2 registration study for cluster headache.

The investor roster here carries its own analytical signal. RA Capital, Perceptive Advisors, and Marshall Wace don’t typically commit capital to pre-IND neurology programs without exhaustive internal scientific review. Their presence alongside Deep Track Capital is not incidental. What makes BETR-001 commercially coherent in a space littered with stalled programs is the combination of three things that rarely come together:

• a validated serotonergic mechanism already embedded in FDA-approved migraine therapies,
• a non-scheduled status that removes the payor and access barriers endemic to psychedelic therapeutics, and
• a clinical signal in humans that predates the current wave of investor interest by fifteen years.

If Phase I data holds against that 2010 benchmark, BetterLife may have secured a more direct path to mainstream neurology than the broader field has yet managed.